[Compound therapy including PSK for malignant head and neck cancer].
The effect of protein-bound polysaccharide preparation, PSK was studied in 44 cases with head and neck cancer. 1) Eight cases with laryngeal cancer received radiation therapy and PSK as immunotherapy, and eight cases as control received radiation alone. During radiation, the mean values of peripheral lymphocyte counts showed statistically significant difference (P less than 0.05) between the cases with immunotherapy and those without immunotherapy. 2) Twenty-eight cases received adjuvant immunochemotherapy with Carboquone and PSK. 22 out of 28 evaluable cases in the group received adjuvant immunochemotherapy were judged as effective. These studies suggest that PSK is one of the valid immunopotentiators.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002225:Carbazilquinone / Q000627:therapeutic use; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011509:Proteoglycans / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D011509:Proteoglycans; D002225:Carbazilquinone; C010770:polysaccharide-K